n early rise in uveal melanoma mortality after enucleation was first observed by Zimmerman et al, 1 who attributed it to metastatic cells being released by the surgery. Since then, such early increases in mortality after ocular therapy have been observed in patients treated not only with enucleation but also with episcleral plaque radiation therapy 2 and proton beam radiation therapy. 2,3 The mortality peak thus reflects the natural evolution of the disease. After the peak, mortality rates return toward baseline, rapidly at first and then more slowly, becoming negligible approximately 25 years after ocular therapy. 4 National population-based cancer registries, such as the Surveillance, Epidemiology, and End Results (SEER) Program, are rich resources of unselected data collected over decades. Such data are amenable to specialized forms of survival analysis wherein a statistical (ie, population-level) cure is achieved when relative survival plateaus, or equivalently, when excess abso-lute risks of death (EAR) return to a normal zero value. Complementing such data are institutional data that characterize the genetic landscape (mutational status) of uveal melanoma. In this study, such data provide a basis for biologic interpretation of waveforms underlying the SEER EAR time course.The goal of this study was to integrate uveal melanoma SEER data and molecularly prognosticated patient data to assess the fraction of patients who survive through times of excess mortality. Conditional on parametric models of EAR, we estimated subtype and total times to cure and fraction of patients alive at time to cure, ie, cured fractions (CF).
MethodsFor SEER data that are deidentified and publicly available, institutional review board approval was not needed. For in-IMPORTANCE The extent to which uveal melanoma is cured by ocular therapy is not known. OBJECTIVE To estimate cured fractions (CF) of uveal melanoma using combination of institutional and Surveillance, Epidemiology, and End Results (SEER) data.